Privium Fund Management B.V. Increases Stock Position in Merck & Co., Inc. $MRK

Privium Fund Management B.V. increased its holdings in Merck & Co., Inc. (NYSE:MRK) by 9.0% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 64,393 shares of the company’s stock after buying an additional 5,300 shares during the quarter. Merck & Co., Inc. comprises approximately 1.0% of Privium Fund Management B.V.’s portfolio, making the stock its 20th biggest position. Privium Fund Management B.V.’s holdings in Merck & Co., Inc. were worth $5,405,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MRK. Chemung Canal Trust Co. boosted its holdings in shares of Merck & Co., Inc. by 21.1% in the third quarter. Chemung Canal Trust Co. now owns 76,338 shares of the company’s stock valued at $6,407,000 after acquiring an additional 13,285 shares in the last quarter. First Pacific Financial boosted its holdings in Merck & Co., Inc. by 14.7% during the third quarter. First Pacific Financial now owns 47,555 shares of the company’s stock worth $3,991,000 after buying an additional 6,082 shares in the last quarter. Diversified Trust Co grew its position in Merck & Co., Inc. by 9.6% in the third quarter. Diversified Trust Co now owns 207,838 shares of the company’s stock worth $17,444,000 after buying an additional 18,187 shares during the last quarter. Caxton Associates LLP increased its holdings in shares of Merck & Co., Inc. by 23.3% in the second quarter. Caxton Associates LLP now owns 39,421 shares of the company’s stock valued at $3,121,000 after buying an additional 7,458 shares in the last quarter. Finally, Live Oak Investment Partners lifted its position in shares of Merck & Co., Inc. by 209.1% during the 2nd quarter. Live Oak Investment Partners now owns 23,949 shares of the company’s stock valued at $1,896,000 after acquiring an additional 16,202 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Zacks highlights strong Keytruda demand and new product launches as key upside drivers into Q4 results, supporting longer?term revenue growth and helping sentiment today. Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings
• Positive Sentiment: Insider/“smart money” activity: Chirfi Guindo bought roughly $1.06M of MRK stock — a buy by an institutional insider can signal confidence and attract momentum buyers. Smart Money Move: Chirfi Guindo Grabs $1.06M Worth Of Merck & Co Stock
• Positive Sentiment: Zacks’ market recap notes MRK outperformed while the broader market dipped, indicating relative strength and sector?specific buying interest. Why the Market Dipped But Merck (MRK) Gained Today
• Neutral Sentiment: Analyst notes and sector coverage (Globe and Mail) provide mixed, mostly informational views on Merck alongside peers—useful for context but not a clear directional trigger. Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Waters (WAT)
• Neutral Sentiment: Additional analyst commentary comparing MRK with UnitedHealth provides sector perspective but no new catalyst. Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and UnitedHealth (UNH)
• Neutral Sentiment: Zacks’ primer on Wall Street estimates and key metrics ahead of Q4 is a useful reference for modeling MRK’s upcoming quarter but doesn’t itself move the needle. Curious about Merck (MRK) Q4 Performance? Explore Wall Street Estimates for Key Metrics
• Neutral Sentiment: Zacks notes MRK is a trending stock on its platform—higher retail/institutional attention increases liquidity and volatility risk but is not a directional catalyst by itself. Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: Zacks warns that declining analyst estimates and rising M&A?related costs could depress near?term results and investor sentiment—key risk ahead of earnings. Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings
• Negative Sentiment: Brokerage consensus is an average “Hold” rating, indicating limited near?term upgrade potential and less bullish analyst conviction. Merck & Co., Inc. (NYSE:MRK) Given Average Rating of “Hold” by Brokerages

Wall Street Analysts Forecast Growth

MRK has been the subject of several recent analyst reports. BMO Capital Markets upgraded shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $82.00 to $130.00 in a report on Thursday, December 18th. UBS Group upped their target price on Merck & Co., Inc. from $105.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Wells Fargo & Company upgraded shares of Merck & Co., Inc. from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $90.00 to $125.00 in a research note on Monday, November 24th. Wall Street Zen raised Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Wolfe Research upgraded shares of Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 target price on the stock in a report on Thursday, January 8th. Eight equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Merck & Co., Inc. currently has an average rating of “Hold” and an average price target of $114.53.

Merck & Co., Inc. Stock Up 1.8%

Shares of NYSE:MRK opened at $110.24 on Friday. The company has a market capitalization of $273.62 billion, a PE ratio of 14.56, a P/E/G ratio of 1.52 and a beta of 0.29. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.44 and a current ratio of 1.66. The company’s fifty day moving average is $105.20 and its 200-day moving average is $91.87. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $112.90.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $1.94 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.08 by ($0.14). Merck & Co., Inc. had a net margin of 29.63% and a return on equity of 44.54%. Equities research analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be given a dividend of $0.85 per share. The ex-dividend date is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 3.1%. Merck & Co., Inc.’s payout ratio is presently 44.91%.

Insider Activity

In related news, EVP David Michael Williams sold 8,614 shares of the firm’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $83.59, for a total value of $720,044.26. Following the transaction, the executive vice president owned 24,578 shares in the company, valued at $2,054,475.02. This trade represents a 25.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.13% of the stock is owned by company insiders.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.